Login to Your Account

Targeting microbiome via small molecules, Enterome raises $16.5M

By Nuala Moran
Staff Writer

Wednesday, April 20, 2016

LONDON – Gut microbiome specialist Enterome Bioscience SA has raised €14.5 million (US$16.5 million) in a series C financing that will fund phase I and phase II development of the lead program in IBD, which is based on small molecules in-licensed earlier this week from Vertex Pharmaceuticals Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription